Oncology Research and Treatment
Journal Abbreviation: Oncol Res Treat
ISSN: 2296-5270
eISSN: 2296-5262
Publisher: Karger Publishers
Publications (241)
CXCR2 expression on neutrophil granulocytes in peripheral tumor is associated with shorter survival in oral squamous cell carcinoma (2022)
Spörl S, Erber R, Gerken M, Wittenberg M, Fischer R, Taxis J, Hartmann A, et al.
Conference contribution
Targeted Inhibition of Protein Biosynthesis sensitizes Cancer Cells to IRE1a-mediated Apoptosis as a Consequence of the unfolded protein response (2022)
Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al.
Conference contribution
Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022)
Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al.
Conference contribution
Immunometabolic alteration in NK cells from multiple myeloma patients (2022)
Jacobs B, Richter S, Stoll A, Völkl S, Mackensen A, Mougiakakos D
Conference contribution
Functional characterization of CD34(+) cells from cryopreserved apheresis of patients with bone marrow-infiltrating malignancies (2022)
Wendland K, Petkovic S, Aigner M, Strobel J, Müller F
Conference contribution
AMBORA Study/AMTS Competence and Advice Center for oral Tumor Therapy (2022)
Schlichtig K
Conference contribution
Foreword of the DGHO Executive Board Vorwort des DGHO-Vorstandes (2022)
Einsele H, Hochhaus A, De Wit M, Schulz CO
Journal article
Clinical trials in hematology and oncology Klinische Studien in der Hämatologie und Onkologie (2022)
Einsele H, Steutel H, Eichhorst B, Gobeler ME, Hochhaus A, Nickel L, Von Messling V, et al.
Journal article
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial (2022)
Goerling U, Gauler T, Dietz A, Grünwald V, Knipping S, Guntinas-Lichius O, Frickhofen N, et al.
Journal article
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study) (2022)
Grünwald V, Hilser T, Meiler J, Goebell P, Ivanyi P, Strauss A, Hartmann A, et al.
Journal article